New hope for Hard-to-Treat cancers: targeted pill aims to halt tumor growth
NCT ID NCT06390839
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This phase II trial is testing the drug palbociclib in 43 patients with advanced cancers that have extra copies of the CDK4 or CDK6 genes. Palbociclib works by blocking signals that tell cancer cells to multiply. The study aims to see if the drug can shrink tumors or slow their growth in these genetically selected cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
palbociclib (a kinase inhibitor pill that blocks cancer cell growth signals)
What this could lead to
If successful, this could provide a new treatment option for patients with advanced cancers that have specific CDK4 or CDK6 gene changes.
What could go wrong
This is a small, early-phase trial (43 patients) with no control group, so results may not apply broadly. The drug may not shrink tumors or improve survival for many participants.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.